NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis → The 7th Trillion Dollar Company? (From The Oxford Club) (Ad) Free AMPH Stock Alerts $43.46 +1.55 (+3.70%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$42.19▼$44.1450-Day Range$38.65▼$44.5752-Week Range$38.43▼$67.66Volume325,090 shsAverage Volume436,594 shsMarket Capitalization$2.13 billionP/E Ratio15.04Dividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amphastar Pharmaceuticals alerts: Email Address Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside51.9% Upside$66.00 Price TargetShort InterestBearish11.35% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.63Based on 10 Articles This WeekInsider TradingSelling Shares$655,145 Sold Last QuarterProj. Earnings Growth18.18%From $3.41 to $4.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.82 out of 5 starsMedical Sector41st out of 920 stocksPharmaceutical Preparations Industry14th out of 399 stocks 3.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.35% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently increased by 3.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 3.7 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest9 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows10 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $655,145.00 in company stock.Percentage Held by Insiders27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 18.18% in the coming year, from $3.41 to $4.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 15.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 15.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 154.09.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 1.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubSeven unknown AI stocks that could DOMINATE the next six years.The original “Magnificent Seven” stocks generated 16,800% over the last 20 years. But now a new set of AI stocks is set to take over.Get the breakdown of this stock from Alex here. About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesMay 3, 2024 | insidertrades.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 500 SharesMay 22 at 4:17 PM | markets.businessinsider.comAmphastar Pharmaceuticals Holds Steady Amidst New Approval and Competitive MarketMay 22 at 11:17 AM | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation AerosolMay 22 at 11:17 AM | finance.yahoo.comAmphastar Receives FDA Approval for Albuterol Sulfate Inhalation AerosolMay 20 at 5:29 AM | seekingalpha.comAmphastar Pharmaceuticals: Profitable Pharma With Strong GrowthMay 16, 2024 | investorplace.comPatent Peril: 3 Stocks at Risk From the FTC's Drug CrusadeMay 15, 2024 | seekingalpha.comReassessing Amphastar PharmaceuticalsMay 15, 2024 | finance.yahoo.comImplied Volatility Surging for Amphastar (AMPH) Stock OptionsMay 15, 2024 | americanbankingnews.comStockNews.com Upgrades Amphastar Pharmaceuticals (NASDAQ:AMPH) to "Buy"May 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)May 12, 2024 | americanbankingnews.comAmphastar Pharmaceuticals (NASDAQ:AMPH) Earns "Hold" Rating from Needham & Company LLCMay 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Reports Strong First Quarter Earnings, Surpassing Analyst Revenue ...May 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.90 (vs US$0.54 in 1Q 2023)May 9, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care ConferenceMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Erasca (ERAS)May 9, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals: Hold Rating Justified Amidst Growth Prospects and Pipeline PotentialMay 9, 2024 | insidermonkey.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 9, 2024 | finance.yahoo.comQ1 2024 Amphastar Pharmaceuticals Inc Earnings CallMay 8, 2024 | investorplace.comAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | washingtonpost.comAmphastar: Q1 Earnings SnapshotMay 7, 2024 | markets.businessinsider.comWhat Wall Street expects from Amphastar Pharmaceuticals's earningsApril 30, 2024 | finance.yahoo.comAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024April 30, 2024 | msn.comFTC Targets ‘Junk’ Patent Listings on Ozempic and Other DrugsApril 18, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy RatingSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/22/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$71.00 Low Stock Price Target$60.00 Potential Upside/Downside+52.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.89 Trailing P/E Ratio14.99 Forward P/E Ratio12.71 P/E Growth1.05Net Income$137.54 million Net Margins22.88% Pretax Margin27.46% Return on Equity29.17% Return on Assets12.11% Debt Debt-to-Equity Ratio0.88 Current Ratio2.18 Quick Ratio1.72 Sales & Book Value Annual Sales$644.40 million Price / Sales3.29 Cash Flow$4.39 per share Price / Cash Flow9.87 Book Value$13.75 per share Price / Book3.15Miscellaneous Outstanding Shares48,900,000Free Float35,650,000Market Cap$2.12 billion OptionableOptionable Beta0.85 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 65)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsAmneal PharmaceuticalsNASDAQ:AMRXRocket PharmaceuticalsNASDAQ:RCKTZai LabNASDAQ:ZLABCatalyst PharmaceuticalsNASDAQ:CPRXVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsEMC Capital ManagementBought 3,113 shares on 5/20/2024Ownership: 0.006%Comerica BankSold 1,179 shares on 5/17/2024Ownership: 0.032%Hancock Whitney CorpBought 2,252 shares on 5/17/2024Ownership: 0.012%Janus Henderson Group PLCSold 6,000 shares on 5/16/2024Ownership: 0.326%California State Teachers Retirement SystemSold 2,886 shares on 5/16/2024Ownership: 0.078%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued twelve-month target prices for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they predict the company's share price to reach $66.00 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2024? Amphastar Pharmaceuticals' stock was trading at $61.85 at the beginning of the year. Since then, AMPH stock has decreased by 29.7% and is now trading at $43.46. View the best growth stocks for 2024 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.84 by $0.03. The firm earned $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 29.17% and a net margin of 22.88%. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Janus Henderson Small Cap Growth Alpha ETF (JSML), ERShares NextGen Entrepreneurs ETF (ERSX), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH), iShares U.S. Pharmaceuticals ETF (IHE) and First Trust Active Factor Small Cap ETF (AFSM). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.68%), Epoch Investment Partners Inc. (1.66%), Price T Rowe Associates Inc. MD (1.20%), Bessemer Group Inc. (0.82%), Mesirow Institutional Investment Management Inc. (0.73%) and Nordea Investment Management AB (0.68%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMPH) was last updated on 5/22/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media41 banks launch ‘crypto dollar’Stansberry ResearchTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademySeven unknown AI stocks that could DOMINATE the next six years.The Oxford Club[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
